• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,283.85
  • 0.68 %
  • $257.68
  • FTSE
  • $8,183.45
  • 0.42 %
  • $34.18
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Rallybio Corporation (RLYB) Stock Price, News & Analysis

Rallybio Corporation (RLYB) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.98

-$0.01

(-1.35%)

Day's range
$0.98
Day's range
$1.05
50-day range
$0.95
Day's range
$1.19
  • Country: US
  • ISIN: US75120L1008
52 wk range
$0.95
Day's range
$3.46
  • CEO: Dr. Stephen Uden M.B, M.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -3.78
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (RLYB)
  • Company Rallybio Corporation
  • Price $0.98
  • Changes Percentage (-1.35%)
  • Change -$0.01
  • Day Low $0.98
  • Day High $1.05
  • Year High $3.46

Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT). The company is also developing RLYB211, a polyclonal anti-HPA-1a antibody that is in a Phase 1/2 clinical trial for the prevention of FNAIT; RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; and RLYB116, a subcutaneously administered inhibitor of C5 for the treatment of patients with paroxysmal nocturnal hemoglobinuria and generalized myasthenia gravis. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 03/11/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.88
  • Trailing P/E Ratio -0.79
  • Forward P/E Ratio -0.79
  • P/E Growth -0.79
  • Net Income $-74,564,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Rallybio Corporation Frequently Asked Questions

  • What were the earnings of RLYB in the last quarter?

    In the last quarter Rallybio Corporation earnings were on Thursday, November, 7th. The Rallybio Corporation maker reported -$0.26 EPS for the quarter, beating analysts' consensus estimates of -$0.35 by $0.09.

  • What is the Rallybio Corporation stock price today?

    Today's price of Rallybio Corporation is $0.98 — it has decreased by -1.35% in the past 24 hours. Watch Rallybio Corporation stock price performance more closely on the chart.

  • Does Rallybio Corporation release reports?

    Yes, you can track Rallybio Corporation's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Rallybio Corporation stock forecast?

    Watch the Rallybio Corporation chart and read a more detailed Rallybio Corporation stock forecast to see what analysts suggest you do with its shares.

  • What is Rallybio Corporation stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by Rallybio Corporation stock ticker.

  • How to buy Rallybio Corporation stocks?

    Like other stocks, RLYB shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Rallybio Corporation's EBITDA?

    Rallybio Corporation measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Rallybio Corporation’s financial statements.

  • What is the Rallybio Corporation's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is 0, which equates to approximately 0.00%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Rallybio Corporation stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Rallybio Corporation's financials relevant news, and technical analysis. Rallybio Corporation's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Rallybio Corporation stock currently indicates a “sell” signal. For more insights, review Rallybio Corporation’s technical analysis.

  • A revenue figure for Rallybio Corporation for its last quarter?

    Rallybio Corporation published it's last quarterly revenues at $299,000.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.